Smear-negative, Culture-positive Pulmonary Tuberculosis: Six-month Chemotherapy with Isoniazid and Rifampin
- 30 April 1990
- journal article
- research article
- Published by American Thoracic Society in American Review of Respiratory Disease
- Vol. 141 (5) , 1232-1235
- https://doi.org/10.1164/ajrccm/141.5_pt_1.1232
Abstract
We have shown in Arkansas (USA) that 9 months of therapy with isoniazid (INH) and rifampin (RIF) can achieve lasting success in 95% of cases with sputum-smear-positive pulmonary tuberculosis. It seemed likely that when the tubercle bacilli were less numerous, i.e., could not be seen on microscopy, less therapy would suffice. Thus, in January 1980, we began giving only 6 months of treatment to patients in whom at least one sputum culture showed (Mycobacterium tuberculosis but at least three sputum smears showed no organisms. The regimen for adults in INH 300 mg and RIF 600 mg daily for 1 month followed by INH 900 mg and RIF 600 mg twice weekly for another 5 months. To date, 286 patients with an average age of 68.2 yr have been treated in this manner. Associated medical conditions were present as "risk factors" in 23.7%. The full course of therapy could not be completed in 75 patients (26.2%), largely because of side effects of the drugs and non-TB deaths in this group of elderly patients. Side effects of the drugs requiring change of drug(s) occurred in 33 patients (11.5%), but major side effects occurred in only eight (2.8%), four (1.4%) with toxic hepatitis and four with hematologic toxicity. The side effects in 25 patients (8.7%) were not life-threatening and were due to drug intolerance. Treatment failed during therapy in only one patient. The full 6-month course of therapy was completed by 211 patients. During follow-up from 3 to 107 months (median, 45 months), five of 211 patients (2.4%) relapsed, all with drug-susceptible organisms. Life table analysis did not show significant difference in survival between patients treated for 6 months (three negative smears) and those treated for 9 months (smear-positive). An overall success of 97% was achieved, which is comparable to the success of 9 months in smear-positive cases. Thus, shortening of therapy for less serious cases can be achieved without loss of effectiveness.This publication has 8 references indexed in Scilit:
- Smear- and Culture-negative Pulmonary Tuberculosis: Four-month Short-course ChemotherapyAmerican Review of Respiratory Disease, 1989
- Short-Course Chemotherapy for Extrapulmonary TuberculosisAnnals of Internal Medicine, 1986
- Short-Course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampinThe American Journal of Medicine, 1984
- 6-MONTHS ISONIAZID-RIFAMPIN THERAPY FOR PULMONARY TUBERCULOSIS - REPORT OF A "UNITED-STATES-PUBLIC-HEALTH-SERVICE COOPERATIVE TRIAL1984
- Undesirable Side Effects of Isoniazid and Rifampin in Largely Twice-Weekly Short-Course Chemotherapy for TuberculosisAmerican Review of Respiratory Disease, 1983
- Whither short-course chemotherapy?Respiratory Medicine, 1981
- Smear-negative pulmonary tuberculosisTubercle, 1980
- The Chemotherapy of Pulmonary Tuberculosis: A ReviewChest, 1979